Switzerland's NLS Pharmaceutics and Israel's Kadimastem are merging to create a joint biopharmaceutical focusing on neurogenerative diseases and diabetes treatments. The merger deal includes stock issuance to Kadimastem shareholders, and both companies plan to divest some assets.